ARTICLE | Company News
Merus, Novartis deal
February 18, 2013 8:00 AM UTC
Merus said it received an undisclosed milestone under a 2010 deal granting Novartis' Novartis Option Fund an option to exclusively license an undisclosed cancer antibody based on Merus' Biclonics and ...